DMRA — Damora Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1800315 ·
Last close
$22.56
Market Cap
$1.40B
52W High
$38.33
52W Low
$15.76
ADV30
483,140
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -36,863,000 | -31,991,000 | 532,627,000 | 349,656,000 | 36,866,000 |
| Jun 2026 | 0 | — | -34,994,000 | -31,174,000 | 543,636,000 | 540,515,000 | 27,577,000 |
| Mar 2026 | 0 | — | -30,811,000 | -27,783,000 | 535,442,000 | 532,899,000 | 23,839,000 |
| Dec 2025 | 0 | — | -201,696,000 | -200,736,000 | 260,527,000 | 257,624,000 | 20,147,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,133,000
Investing CF
$-17,374,000
Financing CF
$330,545,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.77
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-578,311,000
Inventory
—
Receivables
$838,000
ST Investments
$178,822,000
EBIT TTM
$-304,364,000
Pretax Income TTM
$-291,343,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -210,872,000 | -209,839,000 | 260,527,000 | 20,147,000 | 240,380,000 | -6,726,000 |
| Dec 2024 | 0 | -21,292,000 | -21,439,000 | 17,132,000 | 1,301,000 | 15,831,000 | -18,623,000 |
| Dec 2023 | 0 | -36,457,000 | -38,349,000 | 38,227,000 | 5,896,000 | 32,331,000 | -36,911,000 |
| Dec 2022 | 0 | -61,207,000 | -61,624,000 | 73,188,000 | 11,435,000 | 61,753,000 | -42,932,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-262,826,000
OpCashFlow TTM
—
Assets (Latest)
$543,636,000
Forward EPS
$-2.17
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NBTX | Nanobiotix S.A. | $1.39B | $27.45 | — |
| RAPP | Rapport Therapeutics, Inc. | $1.41B | $23.76 | — |
| NUVB | Nuvation Bio Inc. | $1.37B | $3.90 | — |
| ANAB | ANAPTYSBIO, INC | $1.36B | $45.61 | — |
| TYRA | Tyra Biosciences, Inc. | $1.35B | $19.57 | — |
News headlines (Yahoo Finance, 1h cache)
Should Trial Launch Require Action From Damora Therapeutics (DMRA) Investors?
2026-11-06 03:19 · Yahoo
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-05 21:01 · Yahoo
Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
2026-11-04 21:06 · Yahoo
Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at
2026-11-04 14:00 · Yahoo
Damora Therapeutics (DMRA) Stock Looks Above Fair Value On Book Value
2026-10-10 14:21 · Yahoo
Damora Therapeutics (DMRA) Climbed, So What Is Drawing Attention Now?
2026-10-10 05:10 · Yahoo
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-10 20:05 · Yahoo
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
2026-08-05 12:00 · Yahoo
Damora Announces Redomestication from Delaware to Cayman Islands
2026-07-17 12:00 · Yahoo
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer
2026-05-05 17:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.